These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 12214673)

  • 1. Role of human cytochrome P450 (CYP) in the metabolic activation of nitrosamine derivatives: application of genetically engineered Salmonella expressing human CYP.
    Kamataki T; Fujita K; Nakayama K; Yamazaki Y; Miyamoto M; Ariyoshi N
    Drug Metab Rev; 2002 Aug; 34(3):667-76. PubMed ID: 12214673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting the mutagenicity of tobacco-related N-nitrosamines in humans using 11 strains of Salmonella typhimurium YG7108, each coexpressing a form of human cytochrome P450 along with NADPH-cytochrome P450 reductase.
    Fujita K; Kamataki T
    Environ Mol Mutagen; 2001; 38(4):339-46. PubMed ID: 11774366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of human cytochrome P450 (CYP) in the metabolic activation of N-alkylnitrosamines: application of genetically engineered Salmonella typhimurium YG7108 expressing each form of CYP together with human NADPH-cytochrome P450 reductase.
    Fujita K; Kamataki T
    Mutat Res; 2001 Nov; 483(1-2):35-41. PubMed ID: 11600130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic activation of N-alkylnitrosamines in genetically engineered Salmonella typhimurium expressing CYP2E1 or CYP2A6 together with human NADPH-cytochrome P450 reductase.
    Kushida H; Fujita K; Suzuki A; Yamada M; Endo T; Nohmi T; Kamataki T
    Carcinogenesis; 2000 Jun; 21(6):1227-32. PubMed ID: 10837014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic polymorphism of CYP2A6 in relation to cancer.
    Kamataki T; Nunoya K; Sakai Y; Kushida H; Fujita K
    Mutat Res; 1999 Jul; 428(1-2):125-30. PubMed ID: 10517986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction of Salmonella typhimurium YG7108 strains, each coexpressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase.
    Fujita K; Nakayama K; Yamazaki Y; Tsuruma K; Yamada M; Nohmi T; Kamataki T
    Environ Mol Mutagen; 2001; 38(4):329-38. PubMed ID: 11774365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Salmonella tester strain sensitive to promutagenic N-nitrosamines: expression of recombinant CYP2A6 and human NADPH-cytochrome P450 reductase in S. typhimurium YG7108.
    Kushida H; Fujita K; Suzuki A; Yamada M; Nohmi T; Kamataki T
    Mutat Res; 2000 Nov; 471(1-2):135-43. PubMed ID: 11080669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic polymorphism of CYP2A6 as one of the potential determinants of tobacco-related cancer risk.
    Kamataki T; Fujieda M; Kiyotani K; Iwano S; Kunitoh H
    Biochem Biophys Res Commun; 2005 Dec; 338(1):306-10. PubMed ID: 16176798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutagenic activation of betel quid-specific N-nitrosamines catalyzed by human cytochrome P450 coexpressed with NADPH-cytochrome P450 reductase in Salmonella typhimurium YG7108.
    Miyazaki M; Sugawara E; Yoshimura T; Yamazaki H; Kamataki T
    Mutat Res; 2005 Mar; 581(1-2):165-71. PubMed ID: 15725615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [How I was enticed into molecular toxicology].
    Kamataki T
    Yakugaku Zasshi; 2006 Dec; 126(12):1309-18. PubMed ID: 17139156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The stimulatory role of human cytochrome b5 in the bioactivation activities of human CYP1A2, 2A6 and 2E1: a new cell expression system to study cytochrome P450 mediated biotransformation.
    Duarte MP; Palma BB; Gilep AA; Laires A; Oliveira JS; Usanov SA; Rueff J; Kranendonk M
    Mutagenesis; 2005 Mar; 20(2):93-100. PubMed ID: 15728263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment of ten strains of genetically engineered Salmonella typhimurium TA1538 each co-expressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase sensitive to various promutagens.
    Yamazaki Y; Fujita K; Nakayama K; Suzuki A; Nakamura K; Yamazaki H; Kamataki T
    Mutat Res; 2004 Aug; 562(1-2):151-62. PubMed ID: 15279838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Escherichia coli MTC, a human NADPH P450 reductase competent mutagenicity tester strain for the expression of human cytochrome P450 isoforms 1A1, 1A2, 2A6, 3A4, or 3A5: catalytic activities and mutagenicity studies.
    Kranendonk M; Carreira F; Theisen P; Laires A; Fisher CW; Rueff J; Estabrook RW; Vermeulen NP
    Mutat Res; 1999 Apr; 441(1):73-83. PubMed ID: 10224324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK.
    Wang H; Tan W; Hao B; Miao X; Zhou G; He F; Lin D
    Cancer Res; 2003 Nov; 63(22):8057-61. PubMed ID: 14633739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers.
    Ariyoshi N; Miyamoto M; Umetsu Y; Kunitoh H; Dosaka-Akita H; Sawamura Y; Yokota J; Nemoto N; Sato K; Kamataki T
    Cancer Epidemiol Biomarkers Prev; 2002 Sep; 11(9):890-4. PubMed ID: 12223434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of chemopreventive effects of 8-methoxypsoralen against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung adenomas.
    Miyazaki M; Yamazaki H; Takeuchi H; Saoo K; Yokohira M; Masumura K; Nohmi T; Funae Y; Imaida K; Kamataki T
    Carcinogenesis; 2005 Nov; 26(11):1947-55. PubMed ID: 15958517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population.
    Tan W; Chen GF; Xing DY; Song CY; Kadlubar FF; Lin DX
    Int J Cancer; 2001 Mar; 95(2):96-101. PubMed ID: 11241319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative metabolism of the tobacco-specific nitrosamines 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol by rat cytochrome P450 2A3 and human cytochrome P450 2A13.
    Jalas JR; Ding X; Murphy SE
    Drug Metab Dispos; 2003 Oct; 31(10):1199-202. PubMed ID: 12975327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans.
    Kimura M; Yamazaki H; Fujieda M; Kiyotani K; Honda G; Saruwatari J; Nakagawa K; Ishizaki T; Kamataki T
    Drug Metab Dispos; 2005 Sep; 33(9):1361-6. PubMed ID: 15980104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retroviral mediated expression of human cytochrome P450 2A6 in C3H/10T1/2 cells confers transformability by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK).
    Tiano HF; Hosokawa M; Chulada PC; Smith PB; Wang RL; Gonzalez FJ; Crespi CL; Langenbach R
    Carcinogenesis; 1993 Jul; 14(7):1421-7. PubMed ID: 8330360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.